Hospira Introduces Enhanced TheraDoc™ Clinical Surveillance System to Help Hospitals Improve Patient Outcomes and Better Manage Antibiotic Use
-- New features support antimicrobial stewardship programs and assist with National Healthcare Safety Network (NHSN) reporting and documentation --
LAKE FOREST, Ill., June 11, 2012 /PRNewswire/ -- Hospira (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today released an important enhancement to its TheraDoc™ clinical surveillance system designed to support hospital antimicrobial stewardship efforts, with the goal of helping to improve patient outcomes, reduce antimicrobial resistant infections and reduce costs. The new TheraDoc system version 4.5, which further automates the monitoring and reporting of infections and antibiotic use, includes powerful features that can assist pharmacists and infection preventionists in maximizing the benefits of clinical surveillance throughout their organizations.
Improving antibiotic use is a key priority for hospitals nationwide, and antimicrobial stewardship plays a critical role in fighting antimicrobial resistance by ensuring appropriate drug selection, dosing and duration. According to the Centers for Disease Control and Prevention (CDC), studies indicate that nearly 50 percent of antimicrobial use in hospitals is unnecessary or inappropriate, and that the overuse of antibiotics is contributing to the growing challenges posed by Clostridium difficile and other antibiotic-resistant bacteria.
"The upgraded TheraDoc system helps hospitals leverage patient data to improve antibiotic use, combat antimicrobial resistance, and ultimately save lives," said France Pitera , vice president, Clinical Information Technology, Hospira. "The software upgrade also helps hospitals improve antimicrobial utilization reporting -- a result of TheraDoc's early work with the CDC on its Antimicrobial Usage Reporting project. We are committed to being at the forefront of clinical surveillance and reporting, as integrating and exchanging relevant patient information supports efforts to protect patients and improve healthcare quality."
The TheraDoc system version 4.5 features a new electronic medication administration record (eMAR) interface that integrates medical administration records into the TheraDoc system, allowing hospitals to monitor antimicrobial utilization using days of therapy or defined daily dose and export this data to the NHSN. The eMAR interface also helps infection preventionists improve patient care by simplifying the process of isolation management.
Other upgrades include an antimicrobial usage dashboard that displays medication administration data, and antimicrobial alerts that help clinicians monitor duration of therapy, identify de-escalation opportunities, and recognize redundant or duplicate therapies, potentially saving money on antimicrobial drugs. Upgraded NHSN definitions are designed to increase the efficiency and accuracy of NHSN reporting.
This upgrade helps hospitals expand their use of TheraDoc technology, which has shown many benefits for hospitals over more than 10 years. Lori McSorley , an infection preventionist at St. Luke's Hospital, Warren Campus , in New Jersey, said using the TheraDoc system helps significantly reduce the time it takes for NHSN data collection and reporting.
"Before TheraDoc, it would take 10-15 minutes per patient to collect and review surgical site infection data before in putting it into the NHSN system," she said. "Now, information on all of our surgeries, including the start and stop time, class of surgery, and patient ASA [physical status] score, can be obtained automatically through the TheraDoc system. I just click on a surgery, and the data are immediately available for review and exporting to NHSN. I can report information on 10 patients in the time it took me to report one using manual methods."
The new TheraDoc system version 4.5 is being demonstrated at the American Society of Health-System Pharmacists (ASHP) Summer Meeting and Exhibition in Baltimore, through June 12 (Booth #910).
Hospira's TheraDoc Clinical Surveillance System
Hospira's TheraDoc clinical surveillance system has been chosen by more than 440 U.S. hospitals and healthcare facilities, making critical patient information and medical knowledge readily available to help clinicians intervene quickly, prescribe appropriately, and improve the quality of patient care. The TheraDoc Clinical Intelligence™ Platform is the engine that powers several knowledge modules, including the Infection Control Assistant™, Antibiotic Assistant™, ADE Assistant™, Clinical Alerts Assistant™ and Anticoagulation Assistant™. For more information, visit www.theradoc.com or call (801) 415-4400.
Hospira, Inc., is the world's leading provider of injectable drugs and infusion technologies. Through its broad, integrated portfolio, Hospira is uniquely positioned to Advance Wellness™ by improving patient and caregiver safety while reducing healthcare costs. The company is headquartered in Lake Forest, Ill., and has approximately 15,000 employees. Learn more at www.hospira.com.
Private Securities Litigation Reform Act of 1995 --
A Caution Concerning Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the enhanced TheraDoc system. Hospira cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, regulatory, quality, legal, technological and other factors that may affect Hospira's operations and may cause actual results to be materially different from expectations include the risks, uncertainties and factors discussed under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Hospira's latest Annual Report on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission, which are incorporated by reference. Hospira undertakes no obligation to release publicly any revisions to forward-looking statements as the result of subsequent events or developments.
 Centers for Disease Control and Prevention. Get Smart for Healthcare. 2011. http://www.cdc.gov/getsmart/healthcare/. Accessed May 22, 2012.
SOURCE Hospira, Inc.
More by this Source
Hospira Reappoints Dr. Sumant Ramachandra Chief Scientific Officer
May 14, 2013, 09:00 ET
Hospira Convenes Its 2013 Annual Meeting of Shareholders
May 08, 2013, 12:55 ET
Hospira dévoile sa stratégie appareil mondiale
May 02, 2013, 01:34 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.